Inovio Pharmaceuticals
127 hedge funds and large institutions have $171M invested in Inovio Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 50 increasing their positions, 26 reducing their positions, and 10 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 26
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
20% more capital invested
Capital invested by funds: $143M → $171M (+$28.1M)
2% more funds holding
Funds holding: 125 → 127 (+2)
0.78% more ownership
Funds ownership: 3.11% → 3.89% (+0.78%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30% less call options, than puts
Call options by funds: $267K | Put options by funds: $383K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$13.7M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$13.4M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.38M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.44M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.52M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$964K |
| 3 |
Citigroup
New York
|
-$769K |
| 4 |
Morgan Stanley
New York
|
-$471K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$444K |
INO Hedge Fund Activity: Q1 2019 in Review
127 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2019, worth a combined $171M — up 20% from $143M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new INO positions and 10 closed out — a net gain of 3 holders — while 50 added to existing stakes and 26 trimmed.
The largest buyer was Nikko Asset Management Americas, opening a new position worth an estimated $13.7M. The largest seller was Oxford Asset Management, cutting an estimated $1.52M.
- 127 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2019, up from 125 in Q4 2018.
- Funds reported $171M of Inovio Pharmaceuticals stock for Q1 2019, up 20% quarter-over-quarter.
- 13 funds opened new Inovio Pharmaceuticals positions in Q1 2019 and 10 closed out, a net change of +3 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2019 was Nikko Asset Management Americas, an estimated $13.7M added.
- The largest Inovio Pharmaceuticals seller in Q1 2019 was Oxford Asset Management, an estimated $1.52M sold.
Based on aggregated 13F filings for Q1 2019.